Priftin Related Published Studies
Well-designed clinical trials related to Priftin (Rifapentine)
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. [2006.04.15]
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. [2004.06.01]
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. [2003.05.15]
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. [2002.06.01]
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. [2002.01]
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. [2000.03]
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. [1999.05.29]
Single and multiple dose pharmacokinetics of rifapentine in man: part II. [1999.05]
Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. [1999.05]
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. [1998.06]
Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. [1997.10]
[A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous] [1993.02]
Well-designed clinical trials possibly related to Priftin (Rifapentine)
New regimens to prevent tuberculosis in adults with HIV infection. [2011.07.07]
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? [2004.12.15]
[Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis] [1998.07]
Other research related to Priftin (Rifapentine)
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. [2014]
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for
preventing tuberculosis in HIV-negative people at risk of active TB. [2013]
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. [2011.01.04]
Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. [2011]
Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. [2010.08]
Effects of four different meal types on the population pharmacokinetics of
single-dose rifapentine in healthy male volunteers. [2010]
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. [2009.12.01]
Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. [2009.07]
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? [2008.11.01]
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. [2008.11]
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. [2007.12]
Rifapentine for the treatment of pulmonary tuberculosis. [2006.12.01]
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. [2006.07.01]
Pharmacokinetics of rifapentine in children. [2006.05]
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. [2005.12.01]
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. [2005.12.01]
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. [2005.10]
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. [2005.07.01]
Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. [2004.07]
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. [2001.12]
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. [2000.12]
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. [2000.10]
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. [2000.05]
Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. [2000.04]
Rifapentine: its role in the treatment of tuberculosis. [1999.11]
Rifapentine pharmacokinetics in adolescents. [1999.10]
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. [1999.10]
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. [1999.09]
Rifapentine. [1998.10]
Single-dose pharmacokinetics of rifapentine in elderly men. [1998.08]
Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. [1998.06]
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. [1998.05]
Single-dose pharmacokinetics of rifapentine in women. [1998.02]
Rifapentine is active in vitro and in vivo against Toxoplasma gondii. [1996.06]
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. [1994.11]
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. [1993.12]
Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. [1993.03]
Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. [1992.04]
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. [1987.06]
Other possibly related research studies
Treatment alternatives for Mycobacterium kansasii. [2001.04]
Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. [1994.08]
TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice. [1992.06]
In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. [1991.10]
Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. [1990.03]
The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model. [1989]
In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. [2004]
Therapeutic drug monitoring in the treatment of tuberculosis. [2002]
Newer drugs in leprosy. [2001.06]
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. [2001]
[Evaluation of modern antibiotics efficacy at experimental Northern Asia rickettsiosis] [2000]
Role of individual drugs in the chemotherapy of tuberculosis. [2000.09]
Pulmonary tuberculosis. [1999.05]
[Current status and perspectives on the development of rifamycin derivative antibiotics] [1999.01]
Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. [1998.11]
[Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections] [1998.02]
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. [1996.12]
New drugs for tuberculosis. [1995.09]
Antimycobacterial drugs. [1994.06]
[A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis] [2006.08]
Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods. [2006.01.13]
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. [2006.04]
Advances in the diagnosis and treatment of tuberculosis. [2006]
Antituberculosis drugs and hepatotoxicity. [2006.11]
Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. [2006.11.15]
[Development of antituberculous drugs: current status and future prospects] [2006.12]
New drugs in resistant tuberculosis. [2007.05]
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. [2008.06]
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. [2008.09]
Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. [2008.08]
[Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study.] [2008.12.30]
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. [2009.01.01]
New approaches to the treatment of latent tuberculosis. [2008.10]
Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. [2009.07]
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. [2009.06.01]
Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review. [2009.02]
Treatment of latent tuberculosis infection: An update. [2010.05]
Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. [2010.05.15]
Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. [2010.06]
[On the way to shortening tuberculosis treatments: clinical trials of the Unitat d' Investagacio en Tuberculosi de Barcelona supported by the Centers for Disease Control and Prevention] [2010.03]
Neglected diseases caused by bacterial infections. [2010]
Experimental and clinical studies on Rifacinna--the new effective antituberculous drug (review). [2010.01.01]
[The effect of interventional therapy in multimodality treatment on multi-drug resistant pulmonary tuberculosis] [2008.02]
New drugs for tuberculosis treatment. [2011.03]
Recent developments in treatment of latent tuberculosis infection. [2011.03]
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. [2011.05.01]
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. [2011.01.01]
|